一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (348k)  required ID / password
Article in Japanese

Case Report

Long-term survival of >15 years achieved with gefitinib treatment in a lung adenocarcinoma case

Emi Umeshita  Mayuka Yamane  Naomi Iwabu  Kenichi Mukaida  Tetsuya Kubota  Akihito Yokoyama 

Department of Respiratory Medicine and Allergology, Kochi University, Kochi Medical School Hospital

ABSTRACT

A 66-year-old man showed multiple bilateral nodules on chest radiography in 2003. A computed tomography revealed a tumor in the right upper lobe and multiple nodular shadows. He underwent right middle lobectomy and was diagnosed with adenocarcinoma (cT4N0M1, Stage IV), subsequently exhibiting EGFR mutation (exon 21 L858R). He was treated with six courses of carboplatin and paclitaxel in 2004, resulting in progressive disease. He was treated with gefitinib in 2005. He exhibited tumor progression after about 10 years; therefore, gefitinib was discontinued and pemetrexed administration was initiated. After 25 courses of pemetrexed therapy, we discontinued pemetrexed because he developed renal dysfunction. T790M was not detected in his liquid biopsy sample; therefore, gefitinib was re-started in 2017. Currently, he has been alive for 15 years after his diagnosis. Based on this case, we conclude that the re-administration of gefitinib can be considered when the activation of bypass pathway is possible.

KEYWORDS

Gefitinib  Lung adenocarcinoma  Long-term survival  Retreatment 

Received 10 Jan 2020 / Accepted 31 Mar 2020

AJRS, 9(4): 252-256, 2020

Google Scholar